Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Becker-Gruenig, N. Ehlken, M. Gorenflo, A. Hager, M. Halank, H. Klose, M. Lichtblau, A. Meyer, F. Reichenberger, S. Sorichter, R. Speich, S. Ulrich, E. Gruenig (Munich, Dresden, Hamburg, Mönchengladbach, Giessen, Germany; Zurich, Switzerland). Efficacy of exercise training in congenital heart disease associated pulmonary hypertension. Eur Respir J 2012; 40: Suppl. 56, 927

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary arterial hypertension in paediatric and adult patients with congenital heart disease Source: Eur Respir Rev 2009; 18: 154-161 Year: 2009 Hemodynamic assessment of pulmonary hypertension in grown-up congenital heart disease Source: Annual Congress 2012 - Pulmonary circulation: end-points and biomarkers Year: 2012 Changing demographics of pulmonary arterial hypertension in congenital heart disease Source: Eur Respir Rev 2010 19: 308-313 Year: 2010 Effect of sitaxentan in patients with pulmonary arterial hypertension associated to congenital heart diseases Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009 Efficacy and safety of oral bosentan in patients with Down‘s syndrome and pulmonary arterial hypertension due to congenital heart disease Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH Year: 2012 Oxygen desaturation during six-minute walking test in pulmonary arterial hypertension associated with adult cardiac congenital heart disease Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008 The effect of 12 months Bosentan treatment on congenital heart disease associated pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 425s Year: 2006 Nebulised Iloprost for pulmonary arterial hypertension associated with congenital heart disease: one centre's experience Source: Eur Respir J 2001; 18: Suppl. 33, 324s Year: 2001 Comparison of exercise capacity and exercise haemodynamic relationships between severe group 3 pulmonary hypertension and pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 The role of cardiopulmonary exercise testing in assessment of the severity of patients with PAH associated with congenital heart disease. Source: International Congress 2019 – Pulmonary hypertension: clinical Year: 2019 Effect of short-term oxygen therapy on exercise performance in patients with cyanotic congenital heart disease Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021 Initial experience of sildenafil in patients with congenital heart disease (CHD) associated pulmonary arterial hypertension (PAH) Source: Eur Respir J 2006; 28: Suppl. 50, 425s Year: 2006 Effects of exercise training in patients with idiopathic pulmonary arterial hypertension Source: Eur Respir J 2009; 34: 669 Year: 2009 Characteristics of patients with pulmonary arterial hypertension associated with congenital heart disease in the French PAH registry Source: Annual Congress 2011 - Clinical characteristics of patients with pulmonary hypertension Year: 2011 Does sildenafil improves exercise capacity and pulmonary artery hypertension in chronic obstructive pulmonary disease? A controlled trial Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009 Pulmonary hypertension associated with left heart disease Source: Eur Respir Mon 2012; 57: 119-137 Year: 2012 The effects of beta-blocker therapy on heart rate, symptoms and exercise in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Bosentan treatment for pulmonary arterial hypertension related to congenital heart disease: real-world clinical experience in Spain Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Double combination therapy in patients with pulmonary arterial hypertension associated with congenital heart defects Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011